Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Mesenchymal stem cells for recurrent miscarriage.

Ramos FS., Perez J., Ng GK., Veltmeyer JD., Koumjian MP., Lin F.

Narrative Review on Scar, Chronic Inflammation, Immune Modulation, published in J Transl Med (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Transl Med (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
42032691
DOI
10.1186/s12967-026-08179-x

Abstract (original English)

BACKGROUND: Recurrent pregnancy loss (RPL), affecting 1–5% of couples, is frequently driven by immunological dysregulation, including excessive natural killer (NK) cell cytotoxicity, reduced regulatory T cell (Treg) function, Th1/Th17 dominance, and inflammatory cytokine imbalance at the maternal-fetal interface. These abnormalities disrupt immune tolerance to the semi-allogeneic fetus, leading to implantation failure or early miscarriage. Current interventions (e.g. low-dose aspirin/heparin for antiphospholipid syndrome, intravenous immunoglobulin, or corticosteroids) show variable efficacy and limitations, particularly in unexplained cases. Mesenchymal stem cells (MSCs), with proven immunomodulatory, anti-inflammatory, and tissue-repair properties, have gained regulatory approval for severe immune dysregulation conditions like steroid-refractory graft-versus-host disease (GVHD), which shares pathophysiological parallels with immune-mediated RPL, including NK hyperactivity and deficient Treg tolerance. MAIN BODY: MSCs from sources such as bone marrow, adipose tissue, or umbilical cord exert context-dependent effects, secreting anti-inflammatory factors (e.g. IL-10, TGF-β), suppressing pro-inflammatory cytokines, inhibiting cytotoxic NK activity, and promoting Treg expansion and function to restore immune homeostasis. Preclinical studies in abortion-prone mouse models (e.g. CBA

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAbortion, HabitualFemaleMesenchymal Stem CellsAnimalsPregnancyMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research